Imago BioSciences (NASDAQ:IMGO) Downgraded by HC Wainwright

HC Wainwright cut shares of Imago BioSciences (NASDAQ:IMGOGet Rating) from a buy rating to a neutral rating in a report issued on Tuesday, MarketBeat Ratings reports. The firm currently has $36.00 price objective on the stock, up from their previous price objective of $35.00.

IMGO has been the subject of several other research reports. Cowen downgraded shares of Imago BioSciences from an outperform rating to a market perform rating and set a $36.00 price target for the company. in a research report on Monday. Wedbush downgraded shares of Imago BioSciences from an outperform rating to a neutral rating and set a $36.00 price target for the company. in a research report on Monday. Jefferies Financial Group downgraded shares of Imago BioSciences from a buy rating to a hold rating and upped their price target for the company from $35.00 to $36.00 in a research report on Monday. Finally, Cowen downgraded shares of Imago BioSciences to a market perform rating and set a $36.00 price target for the company. in a research report on Tuesday. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Imago BioSciences presently has an average rating of Hold and an average target price of $36.00.

Imago BioSciences Stock Performance

Shares of NASDAQ:IMGO opened at $35.64 on Tuesday. The company has a market cap of $1.21 billion, a PE ratio of -19.37 and a beta of 1.94. Imago BioSciences has a 52 week low of $11.56 and a 52 week high of $35.75. The firm has a 50 day simple moving average of $17.66 and a 200 day simple moving average of $16.24.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Metropolitan Life Insurance Co NY acquired a new position in Imago BioSciences in the 1st quarter valued at approximately $28,000. Ameritas Investment Partners Inc. increased its stake in shares of Imago BioSciences by 108.3% during the 1st quarter. Ameritas Investment Partners Inc. now owns 1,556 shares of the company’s stock worth $30,000 after purchasing an additional 809 shares during the last quarter. Amalgamated Bank acquired a new position in shares of Imago BioSciences during the 1st quarter worth $41,000. Tower Research Capital LLC TRC increased its stake in shares of Imago BioSciences by 305.1% during the 3rd quarter. Tower Research Capital LLC TRC now owns 5,643 shares of the company’s stock worth $85,000 after purchasing an additional 4,250 shares during the last quarter. Finally, Legal & General Group Plc increased its stake in shares of Imago BioSciences by 46.2% during the 2nd quarter. Legal & General Group Plc now owns 6,098 shares of the company’s stock worth $81,000 after purchasing an additional 1,926 shares during the last quarter. Institutional investors and hedge funds own 99.50% of the company’s stock.

About Imago BioSciences

(Get Rating)

Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.

Featured Stories

Analyst Recommendations for Imago BioSciences (NASDAQ:IMGO)

Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.